Literature DB >> 7598789

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.

R Martin1, H F McFarland.   

Abstract

Multiple sclerosis (MS) is the most frequent, demyelinating disease of the central nervous system (CNS) in Northern Europeans and North Americans. Despite intensive research its etiology is still unknown, but a T cell-mediated autoimmune pathogenesis is likely to be responsible for the demyelination. This hypothesis is based both on findings in MS patients and studies of an experimental animal model for demyelinating diseases, experimental allergic encephalomyelitis (EAE). Experiments in EAE have not only demonstrated which myelin antigens are able to induce the demyelinating process but also have determined the characteristics of encephalitogenic T cells, that is, their fine specificity, major histocompatibility complex (MHC) restriction, lymphokine secretion, activation requirements, and T cell receptor (TCR) usage. Based on these findings, highly specific and efficient immune interventions have been designed in EAE and have raised hopes that similar approaches could modulate the disease process in MS. Although the examination of the myelin-specific T cell response in MS patients has shown parallels to EAE, this remains an area of intensive research because a number of questions remain. This review summarizes the important lessons from EAE, examines recent findings in MS, and discusses current concepts about how the disease process develops and which steps might be taken to modulate it.

Entities:  

Mesh:

Year:  1995        PMID: 7598789     DOI: 10.3109/10408369509084683

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  70 in total

1.  LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor.

Authors:  E Koustova; Y Sei; L Fossom; M L Wei; P N Usherwood; N B Keele; M A Rogawski; A S Basile
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Breakdown of the blood-retinal barrier induced by activated T cells of nonneural specificity.

Authors:  P Hu; J D Pollard; T Chan-Ling
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 3.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 4.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

5.  Oligoclonal T cell repertoire in cerebrospinal fluid of patients with inflammatory diseases of the nervous system.

Authors:  D Gestri; L Baldacci; R Taiuti; E Galli; E Maggi; M P Piccinni; M Vergelli; L Massacesi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

Review 6.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Cytosolic phospholipase A₂: physiological function and role in disease.

Authors:  Christina C Leslie
Journal:  J Lipid Res       Date:  2015-04-02       Impact factor: 5.922

Review 8.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

9.  Evidence that the Y chromosome influences autoimmune disease in male and female mice.

Authors:  Cory Teuscher; Rajkumar Noubade; Karen Spach; Benjamin McElvany; Janice Y Bunn; Parley D Fillmore; James F Zachary; Elizabeth P Blankenhorn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-15       Impact factor: 11.205

10.  MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum.

Authors:  Stefanie Kuerten; Dilyana A Kostova-Bales; Lukas P Frenzel; Justine T Tigno; Magdalena Tary-Lehmann; Doychin N Angelov; Paul V Lehmann
Journal:  J Neuroimmunol       Date:  2007-07-25       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.